{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:16:36Z","timestamp":1783433796659,"version":"3.54.6"},"reference-count":46,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Almost 75% of patients with relapsing multiple sclerosis (pwRMS) with suboptimal response to other disease\u2010modifying therapies (DMTs) showed no evidence of disease activity (NEDA\u20103) when treated with ocrelizumab in a large single\u2010arm multicentre trial over 2\u2009years. We aimed to assess the 4\u2010year effectiveness and safety of ocrelizumab in pwRMS who entered a 2\u2010year extension trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PwRMS completing CASTING were eligible to rollover into LIBERTO if available in the country of residence. PwRMS received ocrelizumab every 24\u2009weeks; the same frequency was used for clinical assessments. Primary endpoint was the proportion of patients who had NEDA\u20103 over 4\u2009years. Safety was assessed by rate and nature of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 439 pwRMS rolled over to LIBERTO, of which 68.1% completed the study; most patients discontinued from LIBERTO due to country\u2010specific changes in reimbursement but most remained on ocrelizumab outside the trial. Over 4\u2009years, 79.5% of patients showed no 24\u2010week confirmed disability progression, 87.5% no relapses, and 90.0% no radiological activity. A total of 65.6% of patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009290) showed NEDA\u20103, with the proportion of patients achieving NEDA\u20103 yearly remaining above 84.8%. Over 4\u2009years, infections (72.9% of patients) and infusion\u2010related reactions (44.2%) were the most reported AEs. Serious AEs were reported in 9.3% of patients. Five (1.1%) patients discontinued due to AEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings suggest that switching to ocrelizumab is safe for patients with early RRMS and suboptimal response to previous DMTs, resulting in significant and durable control of disease activity.<\/jats:p>\n                    <jats:p>\n                      Trial Registration: LIBERTO (NCT03599245), extension study to CASTING (NCT02861014); first patient enrolled 12.07.2018;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03599245\">https:\/\/clinicaltrials.gov\/study\/NCT03599245<\/jats:ext-link>\n                      . CHORDS (NCT02637856), ENSEMBLE (NCT03085810)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70628","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:32:52Z","timestamp":1782127972000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4\u2010Year\n                    <scp>CASTING<\/scp>\n                    \u2013\n                    <scp>LIBERTO<\/scp>\n                    Trial"],"prefix":"10.1111","volume":"33","author":[{"given":"Patrick","family":"Vermersch","sequence":"first","affiliation":[{"name":"Inserm U1172 LilNCog, CHU Lille, FHU Precise Univ. Lille  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph H. B.","family":"Benedict","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jacobs School of Medicine and Biomedical Sciences University of Buffalo  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Wijmeersch","sequence":"additional","affiliation":[{"name":"University MS Centre, Pelt, Hasselt University  Hasselt Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"llya","family":"Kister","sequence":"additional","affiliation":[{"name":"New York University Langone Medical Center, NYU Multiple Sclerosis Comprehensive Care Center  New York City New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-5716","authenticated-orcid":false,"given":"Celia","family":"Oreja\u2010Guevara","sequence":"additional","affiliation":[{"name":"Neurology Hospital Clinico San Carlos, Idissc  Madrid Spain"},{"name":"Departmento of Medicina, Faculty of Medicine Complutense University of Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksel","family":"Siva","sequence":"additional","affiliation":[{"name":"Cerrahpa\u015fa School of Medicine Istanbul University  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[{"name":"Clinic of Neurology and Neurophysiology University Hospital Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wuerfel","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouchra","family":"El Azzouzi","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kuenzel","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Buffels","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licinio","family":"Craveiro","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Dirks","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[{"name":"Department of Neurorehabilitation Sciences Casa di Cura Igea  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Genentech I \u201cOCREVUS (Ocrelizumab) [Full Prescribing Information] \u201d2025 https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf."},{"key":"e_1_2_11_3_1","unstructured":"European Medicines Agency \u201cOcrevus [Summary of Product Characteristics] \u201daccessed 18 January 2021 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ocrevus\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010376"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010022\u201001672\u20109"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15171"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22366"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(11)61649\u20108"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008189"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217318760642"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv258"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511435717"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2019.05.010"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.5.962"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053\u2010199304050\u201000006"},{"key":"e_1_2_11_18_1","unstructured":"U.S. Food & Drug Administration \u201cWhat is a Serious Adverse Event? 2016 \u201daccessed 5 February 2026 https:\/\/www.fda.gov\/safety\/reporting\u2010serious\u2010problems\u2010fda\/what\u2010serious\u2010adverse\u2010event."},{"key":"e_1_2_11_19_1","unstructured":"National Cancer Institute \u201cCommon Terminology Criteria for Adverse Events (CTCAE) 2017 \u201daccessed 5 February 2026 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)32388\u20101"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13236"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010023\u201001942\u20100"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211035740"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00095\u20108"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072\u2010024\u201007449\u20100"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104941"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105570"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13760\u2010024\u201002572\u20103"},{"issue":"1","key":"e_1_2_11_29_1","article-title":"Real\u2010World Safety and Effectiveness of Ocrelizumab in Different Treatment Lines in RMS\u2014CONFIDENCE Interim Analysis","volume":"31","author":"Buttmann M.","year":"2024","journal-title":"European Journal of Neurology"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210049"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199907)46:1<79::AID-ANA12>3.0.CO;2-9"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100404.2009.01221.x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102014\u2010309903"},{"issue":"3","key":"e_1_2_11_34_1","article-title":"Two\u2010Year Results of Patient\u2010Reported Outcomes in Patients With Multiple Sclerosis Treated With Ocrelizumab in a Large Real\u2010World Setting: MuSicalE Interim Analysis","volume":"30","author":"Trojano M.","year":"2024","journal-title":"Multiple Sclerosis Journal"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010020\u201000224\u20101"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104375"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.09.009"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.044"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241277736"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516681198"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537\u20102073.2014\u2010035"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101982"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102420"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104245"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231207280"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102454"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1542"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70628","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:38:31Z","timestamp":1783431511000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/ene.70628"],"URL":"https:\/\/doi.org\/10.1111\/ene.70628","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70628"}}